- Home
- DD vs ROIV Comparison
DD vs ROIV Comparison
Compare DD & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DD | ROIV |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 20.7B |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DD | ROIV |
|---|---|---|
| Price | $45.46 | $28.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $62.07 | $27.56 |
| AVG Volume (30 Days) | 3.2M | ★ 4.5M |
| Earning Date | 05-01-2026 | 02-06-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,397,000,000.00 | $29,053,000.00 |
| Revenue This Year | $6.91 | N/A |
| Revenue Next Year | $3.85 | $594.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.34 | $8.73 |
| 52 Week High | $83.40 | $30.33 |
Technical Indicators
Market Signals| Indicator | DD | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 56.22 |
| Support Level | $42.54 | $26.94 |
| Resistance Level | $52.66 | $30.33 |
| Average True Range (ATR) | 1.28 | 0.95 |
| MACD | 0.17 | -0.12 |
| Stochastic Oscillator | 69.76 | 79.20 |
Price Performance
Historical ComparisonAbout DD DuPont de Nemours Inc.
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the healthcare, water, construction, automotive, aerospace, and printing and packaging industries. Healthcare and water will generate the majority of profits.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.